Published in Int J Radiat Oncol Biol Phys on February 01, 1985
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science (1986) 6.33
A novel murine oncornavirus with dual eco- and xenotropic properties. Proc Natl Acad Sci U S A (1975) 5.91
Rapid cell culture assay technic for murine leukaemia viruses. Nature (1971) 5.87
Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A (1986) 5.55
Isolation of murine sarcoma virus-transformed mouse cells which are negative for leukemia virus from agar suspension cultures. Int J Cancer (1970) 5.48
Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science (1985) 5.42
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A (1986) 4.68
Activation of the transforming potential of a normal cell sequence: a molecular model for oncogenesis. Science (1981) 4.27
Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses (1987) 3.67
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol (1990) 3.35
Biological activity of cloned Moloney sarcoma virus DNA: Terminally redundant sequences may enhance transformation efficiency. Proc Natl Acad Sci U S A (1980) 3.29
Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc (1976) 3.19
Quantitative infectivity assay for HIV-1 and-2. Nature (1988) 3.01
Cloning of integrated Moloney sarcoma proviral DNA sequences in bacteriophage lambda. Proc Natl Acad Sci U S A (1979) 2.98
Nucleotide sequences in mouse DNA and RNA specific for Moloney sarcoma virus. Proc Natl Acad Sci U S A (1976) 2.86
Simple, quantitative assay for both xenotropic murine leukemia and ecotropic feline leukemia viruses. J Virol (1974) 2.84
Isolation of RD-114-like oncornavirus from a cat cell line. J Virol (1973) 2.61
Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J Immunol (1990) 2.57
Fractionation of DNA nucleotide transcripts from Moloney sarcoma virus and isolation of sarcoma virus-specific complementary DNA. J Virol (1976) 2.39
Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. Science (1986) 2.35
Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses. J Virol (1987) 2.28
Transformation of mouse 3T3 cells by murine sarcoma virus: release of virus-like particles in the absence of replicating murine leukemia helper virus. Proc Natl Acad Sci U S A (1971) 2.26
Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci U S A (1987) 2.25
Isolation and identification of a helper virus found in the Moloney sarcoma-leukemia virus complex. J Natl Cancer Inst (1969) 1.96
Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J Virol (1988) 1.95
In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol (1986) 1.91
Titration patterns of a murine sarcoma-leukemia virus complex: evidence for existence of competent sarcoma virions. Science (1968) 1.73
Neutralization of homologous and heterologous oncornaviruses by antisera against the p15(E) and gp71 polypeptides of Friend murine leukemia virus. Virology (1976) 1.73
HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis. J Immunol (1987) 1.69
Rate of divergence of cellular sequences homologous to segments of Moloney sarcoma virus. J Virol (1977) 1.65
HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens. J Immunol (1988) 1.63
Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J Virol (1989) 1.61
Revertants of mouse cells transformed by murine sarcoma virus. I. Characterization of flat and transformed sublines without a rescuable murine sarcoma virus. Virology (1972) 1.59
Cells transformed by certain strains of Moloney sarcoma virus contain murine p60. Cell (1977) 1.56
Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas. Proc Natl Acad Sci U S A (1974) 1.54
Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III. J Virol (1987) 1.49
Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A (1987) 1.46
Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci (2001) 1.45
Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci U S A (1986) 1.43
Biological, immunological, and biochemical evidence that HIX virus is a recombinant between Moloney leukemia virus and a murine xenotropic C type virus. Virology (1978) 1.42
Isolation of human amnion cells transformed by rescuable murine sarcoma virus. Nat New Biol (1973) 1.41
Persistent herpes simplex virus infections established in two Burkitt lymphoma derived cell lines. J Gen Virol (1976) 1.38
Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men. Proc Natl Acad Sci U S A (1987) 1.37
A p60 polypeptide in the feline leukemia virus pseudotype of Moloney sarcoma virus with murine leukemia virus p30 antigenic determinants. Proc Natl Acad Sci U S A (1975) 1.37
Oncogenic and immunogenic potential of cloned HIX virus in mice and cats. Med Microbiol Immunol (1977) 1.37
Rescue of murine sarcoma virus from a sarcoma-positive leukemia-negative cell line: requirement for replicating leukemia virus. J Virol (1971) 1.32
Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science (1988) 1.32
Identification of a calmodulin-binding and inhibitory peptide domain in the HIV-1 transmembrane glycoprotein. AIDS Res Hum Retroviruses (1993) 1.32
Relationships between structure and activity of retinoids. Nature (1976) 1.31
Quantitative interactions of feline leukaemia virus and its pseudotype of murine sarcoma virus in cat cells: requirement for DNA synthesis. J Gen Virol (1971) 1.29
Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol (1999) 1.29
Revertants of mouse cells transformed by murine sarcoma virus. 3. Metastable expression of virus functions in revertants retransformed by murine sarcoma virus. Virology (1974) 1.28
Molecular relatedness of mammalian RNA tumor viruses as determined by DNA hybridization. Science (1973) 1.28
Purification of 120,000 dalton envelope glycoprotein from culture fluids of human immunodeficiency virus (HIV)-infected H9 cells. AIDS Res Hum Retroviruses (1987) 1.26
Elimination of the sarcoma genome from murine sarcoma virus transformed cat cells. Science (1976) 1.26
Isolation from cats of an endogenous type C virus with a novel envelope glycoprotein. J Virol (1985) 1.26
Properties of mouse leukemia viruses. I. Characterization of various antisera and serological identification of viral components. Virology (1972) 1.25
Characterization of integrated Moloney Sarcoma proviruses and flanking host sequences cloned in bacteriophage lambda. Cold Spring Harb Symp Quant Biol (1980) 1.24
Inactivation of murine xenotropic oncornavirus by normal mouse sera is not immunoglobulin-mediated. Virology (1976) 1.19
Reversion of murine sarcoma virus transformed mouse cells: variants without a rescuable sarcoma virus. Science (1972) 1.18
T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. J Immunol (1999) 1.18
Productive infection and morphologic alteration of human cells by a modified sarcoma virus. J Natl Cancer Inst (1970) 1.17
Efficient release of murine xenotropic oncornavirus after murine leukemia virus infection of mouse cells. Virology (1975) 1.16
Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1987) 1.14
Genomic masking of nondefective recombinant murine leukemia virus in Moloney virus stocks. Science (1978) 1.14
Radiation leukemia virus: quantitative tissue culture assay. Science (1969) 1.13
Use of an established cat cell line for investigation and quantitation of feline oncornaviruses. J Natl Cancer Inst (1972) 1.13
Viral infection across species barriers: reversible alteration of murine sarcoma virus for growth in cat cells. Science (1969) 1.13
Characterization of RNA from noninfectious virions produced by sarcoma positive-leukemia negative transformed 3T3 cells. Proc Natl Acad Sci U S A (1973) 1.11
Properties of mouse leukemia viruses. II. Isolation of viral components. Virology (1972) 1.10
Activity of vitamin A analogues in cell cultures of mouse epidermis and organ cultures of hamster trachea. Nature (1975) 1.08
Detection of some murine leukemia virus antigens in virus particles derived from 3T3 cells transformed only by murine sarcoma virus. Virology (1972) 1.06
A specific assay measuring binding of 125I-Gp 120 from HIV to T4+/CD4+ cells. J Immunol Methods (1987) 1.05
Simultaneous isolation of simian foamy virus and HTLV-III/LAV from chimpanzee lymphocytes following HTLV-III or LAV inoculation. Arch Virol (1987) 1.05
Phosphorylation and nucleic acid binding properties of m1 Moloney murine sarcoma virus-specific pP60gag. J Virol (1977) 1.05
The G-protein-coupled formylpeptide receptor FPR confers a more invasive phenotype on human glioblastoma cells. Br J Cancer (2010) 1.04
Expression of functional formyl peptide receptors by human astrocytoma cell lines. J Neuroimmunol (2000) 1.03
Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III). Cancer Res (1985) 1.01
HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemia. J Immunol (1987) 1.01
Tissue culture assay of helper activity of murine leukemia virus for murine sarcoma virus. J Natl Cancer Inst (1968) 0.98
Characterization of the serological cross-reactivity between glycoproteins of the human immunodeficiency virus and equine infectious anaemia virus. J Gen Virol (1988) 0.98